209 related articles for article (PubMed ID: 31504814)
1. Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era.
Gill CM; Fowkes M; Shrivastava RK
Neurosurgery; 2020 Feb; 86(2):E118-E123. PubMed ID: 31504814
[TBL] [Abstract][Full Text] [Related]
2. Unraveling molecular advancements in chordoma tumorigenesis and treatment response: a review of scientific discoveries and clinical implications.
Jin MC; Connolly ID; Ravi K; Tobert DG; MacDonald SM; Shin JH
Neurosurg Focus; 2024 May; 56(5):E18. PubMed ID: 38691860
[TBL] [Abstract][Full Text] [Related]
3. Genomic and transcriptomic characterization of skull base chordoma.
Sa JK; Lee IH; Hong SD; Kong DS; Nam DH
Oncotarget; 2017 Jan; 8(1):1321-1328. PubMed ID: 27901492
[TBL] [Abstract][Full Text] [Related]
4. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic targets in chordoma.
Bydon M; Papadimitriou K; Witham T; Wolinsky JP; Bydon A; Sciubba D; Gokaslan Z
Expert Opin Ther Targets; 2012 Nov; 16(11):1139-43. PubMed ID: 22860993
[TBL] [Abstract][Full Text] [Related]
7. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
8. Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma.
Kitamura Y; Sasaki H; Yoshida K
Brain Tumor Pathol; 2017 Apr; 34(2):78-90. PubMed ID: 28432450
[TBL] [Abstract][Full Text] [Related]
9. Clinical findings in families with chordoma with and without T gene duplications and in patients with sporadic chordoma reported to the Surveillance, Epidemiology, and End Results program.
Parry DM; McMaster ML; Liebsch NJ; Patronas NJ; Quezado MM; Zametkin D; Yang XR; Goldstein AM
J Neurosurg; 2020 Jun; 134(5):1399-1408. PubMed ID: 32559743
[TBL] [Abstract][Full Text] [Related]
10. Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases.
Jambhekar NA; Rekhi B; Thorat K; Dikshit R; Agrawal M; Puri A
Arch Pathol Lab Med; 2010 Aug; 134(8):1181-7. PubMed ID: 20670140
[TBL] [Abstract][Full Text] [Related]
11. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas.
Vujovic S; Henderson S; Presneau N; Odell E; Jacques TS; Tirabosco R; Boshoff C; Flanagan AM
J Pathol; 2006 Jun; 209(2):157-65. PubMed ID: 16538613
[TBL] [Abstract][Full Text] [Related]
12. A Diagnostic Pitfall: Atypical Teratoid Rhabdoid Tumor Versus Dedifferentiated/Poorly Differentiated Chordoma: Analysis of a Mono-institutional Series.
Buccoliero AM; Caporalini C; Scagnet M; Baroni G; Moscardi S; Mussa F; Giordano F; Sardi I; Genitori L
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):147-154. PubMed ID: 28777153
[TBL] [Abstract][Full Text] [Related]
13. [Chordomas--diagnostic steps and therapeutic consequences].
Wacker A; Stadler P; Pless M
Dtsch Med Wochenschr; 2002 Jun; 127(25-26):1389-91. PubMed ID: 12075499
[No Abstract] [Full Text] [Related]
14. Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas.
Bell AH; DeMonte F; Raza SM; Rhines LD; Tatsui CE; Prieto VG; Fuller GN; Bell D
Virchows Arch; 2018 Mar; 472(3):489-497. PubMed ID: 28844110
[TBL] [Abstract][Full Text] [Related]
15. The brachyury Gly177Asp SNP is not associated with a risk of skull base chordoma in the Chinese population.
Wu Z; Wang K; Wang L; Feng J; Hao S; Tian K; Zhang L; Jia G; Wan H; Zhang J
Int J Mol Sci; 2013 Oct; 14(11):21258-65. PubMed ID: 24232574
[TBL] [Abstract][Full Text] [Related]
16. Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma.
Kelley MJ; Shi J; Ballew B; Hyland PL; Li WQ; Rotunno M; Alcorta DA; Liebsch NJ; Mitchell J; Bass S; Roberson D; Boland J; Cullen M; He J; Burdette L; Yeager M; Chanock SJ; Parry DM; Goldstein AM; Yang XR
Hum Genet; 2014 Oct; 133(10):1289-97. PubMed ID: 24990759
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.
Shalaby AA; Presneau N; Idowu BD; Thompson L; Briggs TR; Tirabosco R; Diss TC; Flanagan AM
Mod Pathol; 2009 Aug; 22(8):996-1005. PubMed ID: 19407855
[TBL] [Abstract][Full Text] [Related]
18. Poorly differentiated chordoma with whole-genome doubling evolving from a SMARCB1-deficient conventional chordoma: A case report.
Curcio C; Cimera R; Aryeequaye R; Rao M; Fabbri N; Zhang Y; Hameed M
Genes Chromosomes Cancer; 2021 Jan; 60(1):43-48. PubMed ID: 32920865
[TBL] [Abstract][Full Text] [Related]
19. The molecular aspects of chordoma.
Gulluoglu S; Turksoy O; Kuskucu A; Ture U; Bayrak OF
Neurosurg Rev; 2016 Apr; 39(2):185-96; discussion 196. PubMed ID: 26363792
[TBL] [Abstract][Full Text] [Related]
20. Results of Chordoma Patients Treated by Different Approaches in a Single Institution.
Akmansu M; Kurt G; Demircan V; Senturk E
Turk Neurosurg; 2020; 30(3):366-370. PubMed ID: 32020567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
